News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Delays PDUFA On Human Genome Sciences, Inc. (HGSI) and GlaxoSmithKline (GSK) Lupus Drug Benlysta



12/6/2010 8:16:41 AM

Pharmaceutical Business Review -- The US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target date for its priority review of Human Genome Sciences (HGS) and GlaxoSmithKline's (GSK) biologics license application (BLA) for Benlysta (belimumab) as a potential treatment for systemic lupus erythematosus (SLE) from 9 December 2010 to 10 March 2011.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES